Valence8 US’s Solid Biosciences SLDB Stock Holding History

Valence8 US’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,728	Closed	-$110K	–	54
2024 Q3	$110K	Buy	+15,728	New	+$128K	0.05%	51

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Valence8 US's SLDB Position: Q4 2024 in Review

Valence8 US sold out of Solid Biosciences (SLDB) in Q4 2024, closing a stake of 15,728 shares — an estimated $110K sold.

Valence8 US first reported a position in SLDB in Q3 2024 and held it in 1 quarter. The position peaked at $110K in Q3 2024. 90 funds tracked by Wall St. Rank hold SLDB as of Q4 2024.

Valence8 US reported no remaining Solid Biosciences position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 15,728 Solid Biosciences shares in Q4 2024, an estimated $110K.
Valence8 US first reported a position in Solid Biosciences in Q3 2024 and held it in 1 quarter.
Valence8 US's Solid Biosciences position peaked at $110K in Q3 2024.
90 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.